When using IDH inhibitors in the clinic, two main drawbacks should be taken into account: (i) severe adverse effects exist; (ii) several mechanisms are responsible for the resistance of AML cells to these drugs. This evidence concerns the gene IDH2 and acute myeloid leukemia.